REGULATION OF MEMORY T CELL TRAFFICKING BY CORE 2 O-GLYCAN SYNTHESIS

Document text

Principal Investigator: Jeffrey C. Nolz
Organization: OREGON HEALTH & SCIENCE UNIVERSITY
Fiscal Year: 2020
Award: $37,607
Funding agency: National Institute of Allergy and Infectious Diseases

ABSTRACT
The current COVID-19 pandemic is a global health emergency, causing severe respiratory disease requiring
hospitalization and even death in a significant proportion of the human population. Although therapeutic
intervention including novel pharmaceuticals or the passive transfer of immune serum from recovered patients
could provide short-term relief in mortality and morbidity, the development of a successful vaccine will
ultimately be required to prevent the continued spread and seasonal recurrence of this disease within the
human population. However, very little is known about either the quality of adaptive immune response or the
viral antigen targets that are necessary to prevent the infection. Here we propose to evaluate a novel
vaccination approach recently developed in my laboratory that we will now apply to SARS-CoV-2. Specifically,
we will generate Vaccinia virus (VacV) vectors expressing the SARS-CoV-2 Spike (S) protein that have been
engineered to targeted the S protein for MHC-II presentation. Overall, this study will evaluate whether VacV
expressing SARS-CoV-2 S protein could be a potential vaccine candidate and whether the “immunogenicity” of
the S protein can be enhanced by targeting the protein for MHC-II presentation.

Terms: <2019 novel coronavirus><2019-nCoV><Adjuvant><Affinity><Antigen Targeting><Antigens><Antisera><Armed Forces Personnel><Attenuated><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Blood Plasma Cell><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><COVID-19 epidemic><COVID-19 pandemic><COVID19 epidemic><COVID19 pandemic><Cessation of life><Class Switching><Class Switchings><Death><Development><Disease><Disorder><Engineering><FDA approved><Future><Generations><Germinal Center><Glycans><Goals><Hospital Admission><Hospitalization><Human><Ig Somatic Hypermutation><Immune Sera><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunoglobulin Isotype-Switch Recombination><Immunoglobulin Somatic Hypermutation><Immunoglobulin Switch Recombination><Infection><Infection prevention><Isotype Switching><Isotype Switchings><Laboratories><Lung diseases><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Military><Military Personnel><Modern Man><Modified Vaccinia Ankara><Modified Vaccinia Virus Ankara><Morbidity><Morbidity - disease rate><NIAID><National Institute of Allergy and Infectious Disease><Pathway interactions><Patients><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Plasma Cells><Plasmacytes><Polysaccharides><Population><Poxvirus officinale><Prevent infection><Prevention><Production><Proteins><Publishing><Pulmonary Diseases><Pulmonary Disorder><Recombinants><Recurrence><Recurrent><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe acute respiratory syndrome coronavirus 2><Smallpox><Smallpox Vaccine><Structure of germinal center of lymph node><Surface Proteins><Switch Recombination><T memory cell><T4 Cells><T4 Lymphocytes><Therapeutic Intervention><United States><Vaccination><Vaccines><Vaccinia virus><Variola><Viral><Viral Antigens><Viral Vector><Virus><Wuhan coronavirus><adaptive immune response><adaptive immunity><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><design><designing><developmental><disease of the lung><disorder of the lung><global health emergency><immune serum><immunogen><immunogenicity><in vivo><interest><intervention therapy><lung disorder><memory T lymphocyte><mortality><neutralizing antibody><new vaccines><next generation vaccines><novel><novel vaccines><pathogen><pathway><plasmocyte><prevent><preventing><recombinant vaccinia virus><severe acute respiratory syndrome-CoV><small pox><small pox vaccine><somatic hypermutation><theories><trafficking><vaccine candidate><vaccinia vector><vaccinia virus vector><variola major><virus antigen>